Kessler Topaz Meltzer & Check, LLP said on Aug. 22, 2026, that it is investigating potential violations of federal securities laws by Alnylam Pharmaceuticals, Inc. on behalf of investors who purchased or acquired the company’s securities and suffered significant losses. Alnylam reported its second-quarter 2026 financial results on July 30 and said it had lowered its full-year 2026 TTR product sales guidance based on early launch experience in the evolving ATTR-CM market, including normalized second-line volume growth after pent-up demand from patients awaiting a new therapy was met. The company reduced projected total TTR net product revenues by approximately $200 million, after which its stock price fell over 28%. Investors who lost money may have legal rights under federal securities laws and can contact KTMC without cost or obligation.